Lung cancer rebiopsy study aims to uncover immunotherapy resistance
NCT ID NCT04300062
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 29 times
Summary
This study enrolls 50 adults with lung cancer (NSCLC or SCLC) whose disease has progressed while on immunotherapy. Researchers will take a new tumor sample (rebiopsy) to study why the cancer stopped responding. The goal is to learn more about resistance mechanisms, not to provide a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Service de Pneumologie et Oncologie thoracique, Hôpital Ambroise Paré, APHP
RECRUITINGBoulogne-Billancourt, 92100, France
Conditions
Explore the condition pages connected to this study.